【摘要】 目的从分子水平探讨阿魏酸钠治疗各类肾小球疾病所引起的蛋白尿的可能机制。方法确诊为系膜增生性肾小球肾炎以蛋白尿为主要表现的患者43例,随机分为阿魏酸钠治疗组(n=26例,阿魏酸钠0.5g加入5%葡萄糖250ml静滴,每日1次)、丹参对照组(n=17例,丹参30ml加入5%葡萄糖250ml静滴,每日1次),两组均以28天为1疗程,分别于治疗前及治疗后行经皮肾活检,留取肾组织行Nrothern blot及Western blot以检测治疗前后肾组织中内皮素-1(ET-1)的表达差异。结果阿魏酸钠治疗后患者肾组织中ET-1的mRNA及蛋白水平的表达较治疗前显著下降(P=0.0076、P=0.0093)。结论阿魏酸钠可从mRNA及蛋白水平抑制肾组织中ET-1的表达,进而减少尿蛋白,保护肾功能。更多还原

【Abstract】 Objective To explore the molecular mechanism of Sodium Ferulate treating proteinuria caused by different glomerular disease.Methods 43 patients that mesangiopoliferative glomerulonephritis were diagnosed and proteinuria was their main manifestation,they were randomly divided into two groups: Sodium Ferulate group(n=26,Sodium Ferulate 0.5g + 5%GS 250ml,ivgtt,qd×28 days),Dansen group(n=17,Dansen 30ml + 5%GS 250ml,ivgtt,qd×28 days),renal biopsy were committed at pre-treatment and 28 day after treatment,and renal tissues were deserved to testing the difference of endoshelin-1(ET-1) expression with Northern blot and Western blot between pre-treatment and 28 day after treatment.Results The ET-1 expression of mRNA and protein were significantly decreased after Sodium Ferulate wa used (P= 0.0076, P= 0.0093).Conclusions Sodium Ferulate can suppress ET-1 expression of kidney from mRNA and protein level.更多还原